Validation of conversion between mini-mental state examination and montreal cognitive assessment

ABSTRACT Introduction Harmonizing data across cohorts is important for validating findings or combining data in meta‐analyses. We replicate and validate a previous conversion of MoCA to MMSE in PD. Methods We used five studies with 1,161 PD individuals and 2,091 observations measured with both the M...

Full description

Saved in:

Bibliographic Details
Published in	Movement disorders Vol. 31; no. 4; pp. 593 - 596
Main Authors	Lawton, Michael, Kasten, Meike, May, Margaret T., Mollenhauer, Brit, Schaumburg, Martina, Liepelt-Scarfone, Inga, Maetzler, Walter, Vollstedt, Eva-Juliane, Hu, Michele T.M., Berg, Daniela, Ben-Shlomo, Yoav
Format	Journal Article
Language	English
Published	United States Blackwell Publishing Ltd 01.04.2016 Wiley Subscription Services, Inc John Wiley and Sons Inc
Subjects	Aged Brief Report Brief Reports Cohort Studies equating Humans Middle Aged Mini-Mental State Examination Montreal Cognitive Assessment Movement disorders Neuropsychological Tests - statistics & numerical data Parkinson Disease - diagnosis Parkinson's disease Psychiatric Status Rating Scales - statistics & numerical data Psychometrics - standards Parkinson's disease Montreal Cognitive Assessment Mini-Mental State Examination equating
Online Access	Get full text
ISSN	0885-3185 1531-8257 1531-8257
DOI	10.1002/mds.26498

Cover

More Information
Summary:	ABSTRACT Introduction Harmonizing data across cohorts is important for validating findings or combining data in meta‐analyses. We replicate and validate a previous conversion of MoCA to MMSE in PD. Methods We used five studies with 1,161 PD individuals and 2,091 observations measured with both the MoCA and MMSE. We compared a previously published conversion table using equipercentile equating with log‐linear smoothing to our internally derived scores. Results Both conversions found good agreement within and across the studies when comparing true and converted MMSE (mean difference: 0.05; standard deviation: 1.84; median difference: 0; interquartile range: –1 to 1, using internal conversion). Conclusions These results show that one can get a reliable and valid conversion between two commonly used measures of cognition in PD studies. These approaches need to be applied to other scales and domains to enable large‐scale collaborative analyses across multiple PD cohorts. © 2016 International Parkinson and Movement Disorder Society
Bibliography:	Monument Trust Discovery Award from Parkinson's UK Dementias and Neurodegenerative Diseases Research Network (DeNDRoN) TEVA Pharma GmbH UCB Deutschland GE Healthcare Deutsche Parkinsonvereinigung National Institute for Health Research (NIHR) Oxford Biomedical Research Center based at Oxford University Hospitals NHS Trust and University of Oxford Abbott Janssen Research & Development TEVA Pharma ark:/67375/WNG-81VH9D10-S istex:B5DA68E3ADF465F9353610252FEF7EA574C095F4 Paracelsus-Klinike Germany ArticleID:MDS26498 German Research Foundation - No. KA3179/2-1 Full financial disclosures and author roles may be found in the online version of this article. Nothing to report. Relevant conflicts of interest/financial disclosures Funding agencies Meike Kasten has received funding for the EPIPARK study from the German Research Foundation (KA3179/2‐1). DeNoPa was supported by unrestricted grants by the Paracelsus‐Klinike Germany and from TEVA Pharma as well as funding from GE Healthcare and the Deutsche Parkinsonvereinigung. The Oxford Discovery study was funded by the Monument Trust Discovery Award from Parkinson's UK; and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Center based at Oxford University Hospitals NHS Trust and University of Oxford, and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). The ABC‐PD study is supported by Janssen Research & Development, a division of Janssen Pharmaceutica NV. Baseline assessment of the MODEP study has been funded by Abbott. Further funding for the MODEP study has been provided by TEVA Pharma GmbH and UCB Deutschland. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Funding agencies: Meike Kasten has received funding for the EPIPARK study from the German Research Foundation (KA3179/2‐1). DeNoPa was supported by unrestricted grants by the Paracelsus‐Klinike Germany and from TEVA Pharma as well as funding from GE Healthcare and the Deutsche Parkinsonvereinigung. The Oxford Discovery study was funded by the Monument Trust Discovery Award from Parkinson's UK; and supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Center based at Oxford University Hospitals NHS Trust and University of Oxford, and the Dementias and Neurodegenerative Diseases Research Network (DeNDRoN). The ABC‐PD study is supported by Janssen Research & Development, a division of Janssen Pharmaceutica NV. Baseline assessment of the MODEP study has been funded by Abbott. Further funding for the MODEP study has been provided by TEVA Pharma GmbH and UCB Deutschland. Relevant conflicts of interest/financial disclosures: Nothing to report.
ISSN:	0885-3185 1531-8257 1531-8257
DOI:	10.1002/mds.26498